All In Biotech

Drug Trial Radar · NCT06290102

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler With e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants With Asthma (4 to 11 Years Old)

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

May 16, 2024

Primary completion

Oct 1, 2024

Study completion Oct 7, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are: * To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module \[Fp/ABS eMDPI\]) in participants with asthma * To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI) * To compare the PK profiles of ABS between the 2 different strengths of TEV-56248 The secondary objective is: • To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI

Conditions

  • Asthma

Interventions

  • TEV-56248Drug

    Pharmaceutical form: Dry powder Route of administration: Oral inhalation

  • Fp MDPIDrug

    Pharmaceutical form: Dry powder Route of administration: Oral inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Drug Concentration (Cmax) of Fluticasone Propionate (Fp)Time frame: Up to 24 hours postdose
  2. Maximum Observed Plasma Drug Concentration (Cmax) of Albuterol Sulfate(ABS)Time frame: Up to 24 hours postdose
  3. Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for FpTime frame: Up to 24 hours postdose
  4. Area Under the Plasma Drug Concentration-Time Curve from Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for ABSTime frame: Up to 24 hours postdose
  5. Area Under the Plasma Drug Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Fluticasone PropionateTime frame: Up to 24 hours postdose
  6. AUC0-24 of Albuterol SulfateTime frame: Up to 24 hours postdose
  7. Time to Maximum Observed Plasma Drug Concentration (tmax) for FpTime frame: Up to 24 hours postdose
  8. Time to Maximum Observed Plasma Drug Concentration (tmax) for ABSTime frame: Up to 24 hours postdose
  9. Terminal Phase (Apparent Elimination) Half-Life (t½) of FpTime frame: Up to 24 hours postdose
  10. Terminal Phase (Apparent Elimination) Half-Life (t½) of ABSTime frame: Up to 24 hours postdose
  11. Last Measurable Concentration Above the Quantification Limit (Clast) of FpTime frame: Up to 24 hours postdose
  12. Last Measurable Concentration Above the Quantification Limit (Clast) of ABSTime frame: Up to 24 hours postdose
  13. Time of Last Measurable Concentration (tlast) of FpTime frame: Up to 24 hours postdose
  14. Time of Last Measurable Concentration (tlast) of ABSTime frame: Up to 24 hours postdose

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Teva Investigational Site 12010

    Mobile, Alabama

  • Teva Investigational Site 12003

    Long Beach, California

  • Teva Investigational Site 12007

    Miami, Florida

  • Teva Investigational Site 12005

    Miami, Florida

  • Teva Investigational Site 12002

    Miami, Florida

  • Teva Investigational Site 12008

    Lafayette, Louisiana

  • Teva Investigational Site 12011

    Columbia, Missouri

  • Teva Investigational Site 12012

    Oklahoma City, Oklahoma

  • Teva Investigational Site 12001

    Boerne, Texas

  • Teva Investigational Site 12009

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.